Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Research & Development (2016 - 2025)

Adma Biologics' Research & Development history spans 13 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Research & Development rose 251.92% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $4.8 million, up 162.6%, while the annual FY2025 figure was $4.8 million, 162.66% up from the prior year.
  • Research & Development reached $1.4 million in Q4 2025 per ADMA's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.5 million in Q3 2025 to a low of $391000.0 in Q4 2024.
  • Average Research & Development over 5 years is $856700.0, with a median of $840500.0 recorded in 2023.
  • Peak YoY movement for Research & Development: crashed 60.09% in 2024, then skyrocketed 270.87% in 2025.
  • A 5-year view of Research & Development shows it stood at $728928.0 in 2021, then soared by 47.42% to $1.1 million in 2022, then plummeted by 58.49% to $446000.0 in 2023, then dropped by 12.33% to $391000.0 in 2024, then soared by 251.92% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Research & Development are $1.4 million (Q4 2025), $1.5 million (Q3 2025), and $1.0 million (Q2 2025).